BIVV 009

Drug Profile

BIVV 009

Alternative Names: BIVV-009; TNT009

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; True North Therapeutics
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Autoimmune haemolytic anaemia
  • Phase I Bullous pemphigoid; Idiopathic thrombocytopenic purpura; Renal transplant rejection

Most Recent Events

  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 11 Dec 2017 Phase-III clinical trials in Autoimmune haemolytic anaemia in USA (IV)
  • 11 Dec 2017 Updated safety and efficacy data presented at the 59th Annual Meeting of American Society of Haematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top